Quick Answer
Alaunos Therapeutics, Inc. reported Cash and Equivalents of $1.39 million for fiscal year 2025.
Alaunos Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.39M | +26.9% |
| 2024 | $1.09M | -82.0% |
| 2023 | $6.06M | -84.5% |
| 2022 | $39.06M | -48.6% |
| 2021 | $76.05M | -33.9% |
| 2020 | $115.07M | +44.3% |
| 2019 | $79.74M | +29.2% |
| 2018 | $61.73M | -13.0% |
| 2017 | $70.95M | -12.5% |
| 2016 | $81.05M | -42.4% |
| 2015 | $140.72M | +228.8% |
| 2014 | $42.80M | -37.2% |
| 2013 | $68.20M | -7.0% |
| 2012 | $73.31M | -30.0% |
| 2011 | $104.71M | +73.4% |
| 2010 | $60.39M | +23.7% |
| 2009 | $48.84M | +329.2% |
| 2008 | $11.38M | — |
| 2003 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.94M | +15.2% | -32.7% |
| June 30, 2025 | $2.88M | +16.9% | +802.5% |
| March 31, 2025 | $319.0K | -92.3% | -70.8% |
| December 31, 2024 | $1.09M | -82.0% | -35.2% |
| September 30, 2024 | $1.68M | -85.9% | -31.7% |
| June 30, 2024 | $2.46M | -86.6% | -40.6% |
| March 31, 2024 | $4.14M | -82.4% | -31.6% |
| December 31, 2023 | $6.06M | -84.5% | -49.2% |
- Alaunos Therapeutics, Inc. showed an increase of +26.9% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Alaunos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: